{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:55:32Z","timestamp":1753275332704,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Since Food and Drug Administration approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A\u2005+\u2005CHP) as initial therapy for previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), there has been limited research on real-world patient characteristics, treatment patterns, and clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed claims of patients with PTCL treated with frontline A\u2005+\u2005CHP or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) using the Symphony Health Solutions database. Adults with International Classification of Diseases-9\/10 PTCL diagnosis codes who initiated A\u2005+\u2005CHP or CHOP between November 2018 and July 2021 were included. A 1:1 propensity score matching analysis was performed that adjusted for potential confounders between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1344 patients were included (A\u2005+\u2005CHP, n\u2005=\u2005749; CHOP, n\u2005=\u2005595). Before matching, 61% were men; median age at index was 62 (A\u2005+\u2005CHP) and 69 (CHOP) years. The most common A\u2005+\u2005CHP-treated PTCL subtypes were systemic anaplastic large cell lymphoma (sALCL; 51%), PTCL-not otherwise specified (NOS; 30%), and angioimmunoblastic T-cell lymphoma (AITL; 12%); the most common CHOP-treated subtypes were PTCL-NOS (51%) and AITL (19%). After matching, similar proportions of patients treated with A\u2005+\u2005CHP and CHOP received granulocyte colony-stimulating factor (89% vs. 86%, P\u2005=\u2005.3). Fewer patients treated with A\u2005+\u2005CHP received subsequent therapy than CHOP overall (20% vs. 30%, P\u2005&amp;lt;\u2005.001) and specifically with the sALCL subtype (15% vs. 28%, P\u2005=\u2005.025).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Characteristics and management of this real-world PTCL population who were older and had a higher comorbidity burden than that in the ECHELON-2 trial demonstrate the importance of retrospective studies when assessing the impact of new regimens on clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad068","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:26:51Z","timestamp":1679923611000},"page":"520-530","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M","family":"Burke","sequence":"first","affiliation":[{"name":"US Oncology Hematology Research Program, Rocky Mountain Cancer Centers , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-9482","authenticated-orcid":false,"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Seagen Inc., Bothell , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9897","authenticated-orcid":false,"given":"Kristina S","family":"Yu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Seagen Inc., Bothell , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3880-0866","authenticated-orcid":false,"given":"Michelle A","family":"Fanale","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Seagen Inc., Bothell , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-7219","authenticated-orcid":false,"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Real-World Evidence Analytics, Genesis Research , Hoboken, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-4258","authenticated-orcid":false,"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Evidence Strategy, Genesis Research , Hoboken, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-2800","authenticated-orcid":false,"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Seagen Inc., Bothell , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School , Ann Arbor, MI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"20","key":"2023060913480858300_CIT0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"author":"National Cancer Institute","key":"2023060913480858300_CIT0002"},{"issue":"8","key":"2023060913480858300_CIT0003","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am J Hematol."},{"issue":"19","key":"2023060913480858300_CIT0004","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in \u00adperipheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood."},{"issue":"8","key":"2023060913480858300_CIT0005","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Elena","year":"2013","journal-title":"Haematologica."},{"year":"2019","key":"2023060913480858300_CIT0006"},{"key":"2023060913480858300_CIT0007","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","author":"Horwitz","year":"2021","journal-title":"Ann Oncol."},{"issue":"9","key":"2023060913480858300_CIT0008","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma","volume":"23","author":"Laribi","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"2023060913480858300_CIT0009","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"2023060913480858300_CIT0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol."},{"issue":"4","key":"2023060913480858300_CIT0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/fon-2021-1032","article-title":"The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review","volume":"18","author":"Ashaye","year":"2022","journal-title":"Future Oncol."},{"issue":"11","key":"2023060913480858300_CIT0012","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis","volume":"110","author":"AbouYabis","year":"2007","journal-title":"Blood."},{"issue":"25","key":"2023060913480858300_CIT0013","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood."},{"issue":"35-36","key":"2023060913480858300_CIT0014","first-page":"597","article-title":"Propensity score: an alternative method of analyzing treatment effects.","volume":"113","author":"Kuss","year":"2016","journal-title":"Dtsch Arztebl Int."},{"issue":"7","key":"2023060913480858300_CIT0015","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/bloodadvances.2021004269","article-title":"Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients","volume":"6","author":"Mead","year":"2022","journal-title":"Blood Adv."},{"issue":"9","key":"2023060913480858300_CIT0016","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023060913480858300_CIT0017","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ejcts\/ezy167","article-title":"Statistical primer: propensity score matching and its alternatives","volume":"53","author":"Benedetto","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"issue":"4","key":"2023060913480858300_CIT0018","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1213\/ANE.0000000000002787","article-title":"Five steps to successfully implement and evaluate propensity score matching in clinical research studies","volume":"127","author":"Staffa","year":"2018","journal-title":"Anesth Analg."},{"issue":"12","key":"2023060913480858300_CIT0019","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood."},{"issue":"1","key":"2023060913480858300_CIT0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1932296819832653","article-title":"The expanding role of real-world evidence trials in health care decision making","volume":"14","author":"Klonoff","year":"2020","journal-title":"J Diab Sci Technol."},{"issue":"10168","key":"2023060913480858300_CIT0021","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"13","key":"2023060913480858300_CIT0022","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2023060913480858300_CIT0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol."},{"issue":"25","key":"2023060913480858300_CIT0024","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"issue":"12","key":"2023060913480858300_CIT0025","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2023060913480858300_CIT0026","first-page":"171","article-title":"Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome","volume":"82","author":"Zaja","year":"1997","journal-title":"Haematologica."},{"issue":"11","key":"2023060913480858300_CIT0027","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/520\/50514436\/oyad068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/520\/50514436\/oyad068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T15:14:28Z","timestamp":1686323668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/520\/7087085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad068","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,3,27]]}}}